CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited – Prepared by Management)

(Expressed in Canadian Dollars)

OCTOBER 31, 2022

Head Office

Suite 1000 – 355 Burrard Street Vancouver, BC V6C 2G8 Canada

Registered and Records Office

Suite 2900 – 595 Burrard Street Vancouver, BC V7X 1J5 Canada

NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these financial statements in accordance with standards established by the Canadian Institute of Chartered Accountants for a review of interim financial statements by an entity's auditor

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Expressed in Canadian Dollars) (Unaudited – Prepared by Management) AS AT,

	October 31, April 3 2022 202
ASSETS	
Current Cash	\$ 7,505 \$ 24,41
Receivables Prepaid expenses	11,609 4,20 113,002 25,25
	132,116 53,86
Exploration and evaluation assets (Note 3)	2,680,014 2,676,09
	\$ 2,812,130 \$ 2,729,95
LIABILITIES AND SHAREHOLDERS' EQUITY	
Current Accounts payable and accrued liabilities (Notes 4 and 7) Convertible securities (Note 5)	\$ 369,515 \$ 263,29 548,291 788,08
	917,806 1,051,38
Shareholders' equity Share capital (Note 6)	8,925,713 8,389,68
Share-based payment reserve (Note 6)	1,183,498 1,183,49
Subscriptions receivable (Note 6) Deficit	(34,930) (34,93 (8,179,957) (7,859,68
	1,894,324 1,678,57
	\$ 2,812,130 \$ 2,729,95
Nature and continuance of operations (Note 1) Subsequent events (Note 11)	
On behalf of the Board:	
"Albert (Rick) Timcke" "Jason Bahnsen" Director	Director

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS

(Expressed in Canadian Dollars)

(Unaudited – Prepared by Management)

FOR THE SIX MONTHS ENDED OCTOBER 31,

	Th	ree months	Tl	hree months		Six months		Six months
	pe	eriod ended	p	eriod ended	p	period ended	p	eriod ended
	(October 31,		October 31,		October 31,		October 31,
		2022		2021		2022		2021
EXPENSES								
Filing and regulatory fees	\$	27,582	\$	18,574	\$	39,091	\$	27,542
Foreign exchange		3,937		2,627		3,996		(25,715)
Interest expenses		-		59,659		-		96,621
Loss on fair value of convertible securities (Note 5)		42,607		-		68,731		-
Management fees (Note 7)		45,000		45,000		90,000		90,000
Office and miscellaneous		4,980		15,203		11,764		27,004
Professional fees (Note 7)		10,212		20,210		35,652		28,840
Promotion and advertisement		45,968		55,001		69,354		109,939
Share-based compensation (Notes 6 and 7)		-		16,251		-		44,427
Travel and accommodation		247		3,311		1,688		5,665
Loss and comprehensive loss for the period	\$	(180,533)	\$	(235,836)	\$	(320,276)	\$	(404,323)
Basic and diluted loss per common share	\$	(0.01)	\$	(0.02)	\$	(0.02)	\$	(0.04)
Weighted average number of common shares outstanding	<u> </u>	13,477,402		10,832,435		13,395,192		10,829,751

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

(Expressed in Canadian Dollars)

(Unaudited – Prepared by Management)

	Number of Shares	S	hare Capital	Su	Share bscriptions	Reserves	Deficit	Convertible curity – equity portion	Sl	Total hareholder's Equity
Balance, April 30, 2021	10,827,067	\$	7,729,758	\$	(34,930)	\$ 983,993	\$ (6,698,090)	\$ -	\$	1,980,731
Convertible securities	-		-		-	-	-	143,111		143,111
Convertible securities – transaction costs	312,274		187,365		-	149,400	-	-		336,765
Convertible securities – converted	180,000		108,000		-	-	-	(24,560)		83,440
Share-based payments	-		-		-	44,427	-	-		44,427
Net loss for the period	-		-		-	-	(404,323)	-		(404,323)
Balance, October 31, 2021	11,319,341		8,025,123		(34,930)	1,177,820	(7,102,413)	118,551		2,184,151
Convertible securities – converted	1,806,289		317,725		-	-	-	(118,551)		119,174
Share-based payments	-		-		-	5,678	-	-		5,678
Exploration and evaluation assets	187,348		46,837		-	-	-	-		46,837
Net loss for the period	-		-		-	-	(757,268)	-		(757,268)
Balance, April 30, 2022	13,312,978		8,389,685		(34,930)	1,183,498	(7,859,681)			1,678,572
Private placement	4,550,000		227,500		-	-	-	-		227,500
Convertible securities – converted	10,552,992		308,528		-	-	-	-		308,528
Net loss for the period	-		-		-	-	(320,276)	-		(320,276)
Balance, October 31, 2022	28,415,970	\$	8,925,713	\$	(34,930)	\$ 1,183,498	\$ (8,179,957)	\$ -	\$	1,894,324

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

(Expressed in Canadian Dollars)

(Unaudited – Prepared by Management) FOR THE SIX MONTHS ENDED OCTOBER 31,

	_	2022		2021
CASH FLOWS FROM OPERATING ACTIVITIES				
Loss for the period	\$	(320,276)	\$	(404,323)
•		` , ,	·	, , ,
Non-cash items:				
Loss on fair value of convertible securities		68,731		-
Share-based payments		-		44,427
Accretion interest on convertible security		-		96,621
Changes in non-cash working capital items:				
Receivables		(7,409)		7,762
Prepaid expenses		(87,752)		(2,098)
Accounts payable and accrued liabilities		106,223		(36,411)
Net cash used in operating activities		(240,483)		(294,022)
CASH FLOWS FROM INVESTING ACTIVITIES				
		(2.024)		(422 211)
Exploration and evaluation expenditures Net cash used in investing activities		(3,924)		(422,211) (422,211)
Net cash used in investing activities		(3,924)		(422,211)
CASH FLOWS FROM FINANCING ACTIVITIES				
Proceeds from private placements		227,500		-
Proceeds from convertible debenture		-		966,089
Net cash provided by financing activities		227,500		966,089
Change in cash for the period		(16,907)		249,856
Cash, beginning of period		24,412		427,820
Cash, end of period	\$	7,505	\$	677,676
CUDDI EMENTAL DICCI OCUDE WITH DECDECT TO CACH ELOWC				
SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS Convertible securities – transaction costs	\$		\$	479,876
Convertible securities – transaction costs Convertible securities converted	\$ \$	308,528	\$ \$	108,000
Exploration and evaluation assets included in accounts payable and accrued liabilities	\$	58,939	\$	-
The state of the s	т	,	-	

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Expressed in Canadian Dollars) (Unaudited – Prepared by Management) FOR THE SIX MONTHS ENDED OCTOBER 31, 2022

1. NATURE AND CONTINUANCE OF OPERATIONS

Northern Lights Resources Corp. (the "Company") was incorporated under the laws of British Columbia on March 28, 2007. The Company's principal business activities include the acquisition and exploration of resource properties. On June 28, 2012, the Company completed its initial public offering ("IPO") by way of prospectus, and a listing on the Canadian Securities Exchange ("CSE"). On February 1, 2021 the Company received DTC and Blue Sky clearance trading on the OTC QB under the symbol "NLRCF".

On May 26, 2022, the Company consolidated its common shares on a ten for one basis. These condensed interim consolidated financial statements reflect the share consolidation on a retrospective basis.

The Company has incurred losses since inception, and will require additional funds to maintain its activities for the upcoming fiscal year. The Company's ability to continue as a going concern is therefore dependent on its ability to raise additional funds through equity issuances. These events and conditions suggest a material uncertainty which may cast significant doubt on the Company's ability to continue as a going concern.

These condensed interim consolidated financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The continuing operations of the Company are dependent upon its ability to continue to raise adequate financing and to commence profitable operations in the future. The condensed interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company's business or ability to raise funds.

2. SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The condensed interim consolidated financial statements have been prepared on a historical cost basis, except for certain financial instruments that have been recorded at fair value. The condensed interim consolidated financial statements are presented in Canadian dollars which is the functional currency of the Company and its subsidiaries.

These condensed interim consolidated financial statements, including comparatives have been prepared using accounting policies consistent with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and in accordance with International Accounting Standards ("IAS") 34, Interim Financial Reporting.

The policies applied in these condensed interim consolidated financial statements are presented below and are based on IFRS issued and outstanding as of October 31, 2022. Any subsequent changes to IFRS that are given effect in our annual consolidated financial statements for the year ending April 30, 2023 could result in restatements of these condensed interim consolidated financial statements. None of these standards are expected to have a significant effect on the condensed interim consolidated financial statement.

The Board of Directors approved these condensed interim consolidated financial statements on December 29, 2022.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in Canadian Dollars)

(Unaudited – Prepared by Management)

FOR THE SIX MONTHS ENDED OCTOBER 31, 2022

2. SIGNIFICANT ACCOUNTING POLICIES (cont'd...)

Basis of consolidation

These condensed interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Secret Pass LLC, a company incorporated under the laws of Arizona, USA, and Rudy Valley Minerals LLC, a company incorporated under the laws of Nevada. At October 31, 2022, the principal activity of the Company's subsidiaries was that of holding companies. Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee.

Specifically, the Company controls an investee if and only if the Company has all the following: (a) power over the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability to use its power over the investee to affect the amount of the investor's returns. All inter-company transactions and balances have been eliminated upon consolidation.

Estimates and judgments

The preparation of the Company's consolidated financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are continually evaluated and are based on management's experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Actual results could differ from these estimates.

The areas which require management to make significant judgments, estimates and assumptions in determining carrying values include, but are not limited to:

Significant Judgments

a. Economic recoverability and probability of future benefits of exploration and evaluation costs

Management has determined that exploration, evaluation and related costs incurred which were capitalized may have future economic benefits and may be economically recoverable. Management uses several criteria in its assessment of economic recoverability and probability of future economic benefits including geologic and other technical information, history of conversion of mineral deposits with similar characteristics to its own properties to proven and probable mineral reserves, the quality and capacity of existing infrastructure facilities, evaluation of permitting and environmental issues and local support for the project.

b. Deferred taxes

The Company recognizes the deferred tax benefit related to deferred and resource tax assets to the extent recovery is probable. Assessing the recoverability of deferred tax assets requires management to make significant estimates of future taxable profit. In addition, future changes in tax laws could limit the ability of the Company to obtain tax deductions from deferred and resource tax assets.

c. Convertible securities

The Company has issued convertible securities as described in Note 5. The accounting for convertible securities, a complex compound financial instrument, requires the Company to determine the classification of the component parts of the convertible securities, which requires significant judgment on whether there are components of equity, liabilities or embedded derivatives.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Expressed in Canadian Dollars)

(Unaudited – Prepared by Management)

FOR THE SIX MONTHS ENDED OCTOBER 31, 2022

2. SIGNIFICANT ACCOUNTING POLICIES (cont'd...)

Estimates and judgments (cont'd...)

d. Functional currency

Judgment was applied in determining the functional currency of the Company and each of its subsidiaries after considering the primary economic environment in which the Company undertakes its financing activities, retains funds and the currency that influences exploration and administration costs.

Significant Estimates

a. Share-based payments

Share-based payments are measured using the Black-Scholes option pricing model based on the estimated fair value of the share-based awards at the date of grant and is expensed to profit or loss over each award's vesting period. The Black-Scholes option pricing model utilizes subjective assumptions such as expected price volatility and expected life of the option. Changes in these input assumptions can significantly affect the fair value estimate.

Foreign exchange

The functional currency is the currency of the primary economic environment in which the entity operates and has been determined for each entity within the Company. The functional currency for all entities within the Company is the Canadian dollar. The functional currency determinations were conducted through an analysis of the consideration factors identified in International Accounting Standard ("IAS") 21, *The Effects of Changes in Foreign Exchange Rates*.

Transactions in currencies other than the Canadian dollar are recorded at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, the monetary assets and liabilities of the Company that are denominated in foreign currencies are translated at the rate of exchange at the consolidated statement of financial position date while non-monetary assets and liabilities are translated at historical rates. Revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Exchange gains and losses arising on translation are reflected in profit or loss for the period.

Loss per share

The Company computes the dilutive effect of options, warrants and similar instruments. Under this method the dilutive effect on loss per share is based on the use of the proceeds that could be obtained upon exercise of options, warrants and similar instruments. It assumes that the proceeds would be used to purchase common shares at the average market price during the year. Basic loss per common share is calculated using the weighted average number of common shares outstanding during the period.

Exploration and evaluation assets

Upon acquiring the legal right to explore an exploration and evaluation asset, costs related to acquisition, exploration and evaluation are capitalized by property. The capitalized costs are presented as either tangible, or intangible exploration and evaluation assets according to the nature of the assets acquired. Expenses related to exploration and evaluation include topographical, geological, geochemical, and geophysical studies, exploration drilling, trenching, sampling and other costs related to the evaluation of the technical feasibility and commercial viability of extracting a mineral resource. The various costs are capitalized on a property-by-property basis pending determination of the technical feasibility and commercial viability of extracting a mineral resource. These assets are recognized as intangible assets and are carried at cost less tax credits related to these expenses and any accumulated impairment losses. No depreciation expenses are recognized for these assets during the exploration and evaluation phase.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Expressed in Canadian Dollars) (Unaudited – Prepared by Management) FOR THE SIX MONTHS ENDED OCTOBER 31, 2022

2. SIGNIFICANT ACCOUNTING POLICIES (cont'd...)

Exploration and evaluation assets (Cont'd...)

If commercially profitable ore reserves are developed, capitalized costs of the related exploration and evaluation assets are reclassified as mining assets and amortized using the unit of production method. If, after management review, it is determined that capitalized acquisition, exploration and evaluation costs are not recoverable, or the exploration and evaluation assets are abandoned, or management deems there to be an impairment in value, the exploration and evaluation assets are written down to their recoverable amount.

Any option payments received by the Company from third parties or tax credits refunded to the Company are credited to the capitalized cost of the exploration and evaluation assets.

If payments received exceed the capitalized cost the excess is recognized as income in the year received. The amounts shown for exploration and evaluation assets do not necessarily represent present or future values. Their recoverability is dependent upon the discovery of economically recoverable reserves, the ability of the Company to obtain the necessary financing to complete the exploration and evaluation, and future profitable production or proceeds from the disposition thereof.

Impairment

At the end of each reporting period, the Company's assets are reviewed to determine whether there is any indication that those assets may be impaired. If such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment, if any. The recoverable amount is the higher of fair value less costs of disposal and value in use. Fair value is determined as the amount that would be obtained from the sale of the asset in an arm's length transaction between knowledgeable and willing parties. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount and the impairment loss is recognized in the profit or loss for the period. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the cash generating unit to which the asset belongs.

Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but to an amount that does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss.

Convertible securities

The Company's convertible securities are segregated into their debt and equity components or derivative liability components at the date of issue, in accordance with the substance of the contractual agreements.

The conversion feature of the convertible securities is presumed to be classified as a derivative financial liability unless it meets all the criteria to recognize as equity instrument. One of criteria is that the conversion option exchanges a fixed amount of shares for a fixed amount of cash ("fixed for fixed"). If the conversion feature meets the fixed for fixed criteria, the conversion option will be classified as equity. The Company has convertible securities which are classified entirely as liabilities because they were issued in a currency other than the functional currency of the Company. As the instrument contains an embedded derivative, it has been designated as at fair value through profit or loss on initial recognition and as such the embedded conversion feature is not separated. All transaction costs related to financial instruments designated as at fair value through profit or loss are expensed as incurred. The component of fair value changes relating to the Company's own credit risk is recognized in other comprehensive income. Amounts recorded in OCI related to credit risk are not subject to recycling in profit or loss, but are transferred to retained earnings when realized. Fair value changes relating to market risk are recognized in profit or loss.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Expressed in Canadian Dollars) (Unaudited – Prepared by Management)

FOR THE SIX MONTHS ENDED OCTOBER 31, 2022

2. SIGNIFICANT ACCOUNTING POLICIES (cont'd...)

Share-based payments

The Company grants stock options to acquire common shares of the Company to directors, officers, employees and consultants. An individual is classified as an employee when the individual is an employee for legal or tax purposes, or provides services similar to those performed by an employee.

The fair value of stock options is measured on the date of grant, using the Black-Scholes option pricing model, and is recognized over the vesting period. Consideration paid for the shares on the exercise of stock options is credited to share capital, and the fair value of the options exercised is transferred from share-based payment reserve to share capital.

In situations where equity instruments are issued to non-employees and some or all of the goods or services received by the entity as consideration cannot be specifically identified, they are measured at fair value of the share-based payment. Otherwise, share-based payments are measured at the fair value of goods or services received.

Income taxes

Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax expense is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at period end, adjusted for amendments to tax payable with regards to previous years.

Deferred tax is recorded using the liability method, providing for temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes; the initial recognition of assets or liabilities that affect neither accounting nor taxable loss; nor differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the statement of financial position date.

A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized.

Additional income taxes that arise from the distribution of dividends are recognized at the same time as the liability to pay the related dividend. Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.

Financial instruments

Financial assets and financial liabilities are recognized on the condensed interim consolidated statements of financial position when the Company becomes a party to the contractual provisions of the financial instrument.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in Canadian Dollars)

(Unaudited – Prepared by Management)

FOR THE SIX MONTHS ENDED OCTOBER 31, 2022

2. SIGNIFICANT ACCOUNTING POLICIES (cont'd...)

Financial instruments (Cont'd...)

The following is the Company's accounting policy for financial instruments under IFRS 9:

Classification

The Company classifies its financial instruments in the following categories: at fair value through profit or loss ("FVTPL"), at fair value through other comprehensive income (loss) ("FVTOCI") or at amortized cost. The Company determines the classification of financial assets at initial recognition. The classification of debt instruments is driven by the Company's business model for managing the financial assets and their contractual cash flow characteristics. Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election (on an instrument-by instrument basis) to designate them as at FVTOCI. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or if the Company has opted to measure them at FVTPL.

Measurement

Financial assets and liabilities at amortized cost

Financial assets and liabilities at amortized cost are initially recognized at fair value plus or minus transaction costs, respectively, and subsequently carried at amortized cost less any impairment.

Financial assets and liabilities at FVTPL

Financial assets and liabilities carried at FVTPL are initially recorded at fair value and transaction costs are expensed in profit or loss. Realized and unrealized gains and losses arising from changes in the fair value of the financial assets and liabilities held at FVTPL are included in profit or loss in the period in which they arise.

Debt investments at FVOCI

These assets are subsequently measured at fair value. Interest income is calculated using the effective interest method, foreign exchange gains and losses and impairment are recognized in profit or loss. Other net gains and losses are recognized in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss.

Equity investments at FVOCI

These assets are subsequently measured at fair value. Dividends are recognized as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognized in OCI and are never reclassified to profit or loss.

Impairment of financial assets at amortized cost

The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve month expected credit losses. The Company shall recognize in profit or loss, as an impairment gain or loss, the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in Canadian Dollars)

(Unaudited – Prepared by Management)

FOR THE SIX MONTHS ENDED OCTOBER 31, 2022

2. SIGNIFICANT ACCOUNTING POLICIES (cont'd...)

Financial Instruments (Cont'd...)

Derecognition

Financial assets

The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity.

Financial liabilities

The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled, or expired. The Company also derecognizes a financial liability when the terms of the liability are modified such that the terms and / or cash flows of the modified instrument are substantially different, in which case a new financial liability based on the modified terms is recognized at fair value.

Gains and losses on derecognition are generally recognized in profit or loss.

The Company's financial assets and liabilities are recorded and measured as follows:

Asset or liability	Category	Measurement	
Cash	FVTPL	Fair value	
Accounts payable and accrued liabilities	Amortized cost	Amortized cost	
Convertible securities	FVTPL	Fair value	

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in Canadian Dollars)

(Unaudited – Prepared by Management)

FOR THE SIX MONTHS ENDED OCTOBER 31, 2022

3. EXPLORATION AND EVALUATION ASSETS

		Secret Pass		Medicine Springs		Total
Acquisition Costs:						
Balance at April 30, 2021	\$	615,049	\$	325,275	\$	940,324
Common shares				46,837		46,837
Balance at April 30, 2022 and						
October 31, 2022	\$	615,049	\$	372,112	\$	987,161
Exploration Costs:						
Balance at April 30, 2021	\$	440,121	\$	231,345	\$	671,466
Assay	,	95,755	·	-	·	95,755
Consulting		49,203		-		49,203
Drilling		443,136		-		443,136
Field work		429,369				429,369
Balance at April 30, 2022		1,457,584		231,345		1,688,929
Field work		3,924		-		3,924
Balance at October 31, 2022	\$	1,461,508	\$	231,345	\$	1,692,853
Balance at April 30, 2022	\$	2,072,633	\$	603,457	\$	2,676,090
Balance at October 31, 2022	\$	2,076,557	\$	603,457	\$	2,680,014

Medicine Springs

The Company entered into a mineral property option agreement dated August 20, 2017, and amended, to acquire 100% of the property in southeastern Elko County, Nevada.

The Medicine Springs property located on the eastern edge of the Carlin Trend in southeastern Elko County, consists of 149 unpatented Federal mineral claims.

The option agreement is a 6 phase exploration agreement. Completion of all of the phases under the agreement is subject to staged cash payments of USD \$950,000, equity consideration of USD \$250,000 and incurring exploration expenditures of USD \$2,700,000. The agreement was amended in July 2020 to extend certain due dates.

The Company has the option to proceed with each subsequent Phase in the option agreement upon the completion of all cash and equity consideration payments to the vendors in addition to meeting the minimum exploration expenditure payments defined for each Phase of the Option Agreement.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in Canadian Dollars)

(Unaudited – Prepared by Management)

FOR THE SIX MONTHS ENDED OCTOBER 31, 2022

3. EXPLORATION AND EVALUATION ASSETS (Cont'd...)

Medicine Springs (cont'd...)

- i) Cash payments
 - a) Phase 1B USD \$25,000 within 30 days of receipt of regulatory approval (paid).
 - b) Phase 2 USD \$50,000 by December 31, 2020 ("Phase 2 Commencement Date") (paid).
 - c) Phase 3 USD \$100,000 by December 31, 2021 ("Phase 3 Commencement Date") (below paid by joint venture partner).
 - d) Phase 4 USD \$150,000 within 30 days of completion of all Phase 3 requirements ("Phase 4 Commencement Date").
 - e) Phase 5 USD \$200,000 within 30 days of completion of all Phase 4 requirements ("Phase 5 Commencement Date").
 - f) Phase 6 USD \$425,000 within 30 days of completion of all Phase 5 requirements ("Phase 6 Commencement Date").

ii) Share issuance

- a) Phase 2 issuance of common shares with a value of USD \$50,000 by December 31, 2020 (issued 133,065 common shares fair valued at \$33,266).
- b) Phase 3 issuance of common shares with a value of USD \$50,000 by December 31, 2021 (issued 187,348 common shares fair valued at \$46,837).
- c) Phase 4 issuance of common shares with a value of USD \$50,000 after the Phase 4 Commencement Date.
- d) Phase 5 issuance of common shares with a value of USD \$50,000 after the Phase 5 Commencement Date.
- e) Phase 6 issuance of common shares with a value of USD \$50,000 after the Phase 6 Commencement Date.

iii) Exploration expenditures

- a) incur USD \$25,000 in exploration upon execution of the agreement (incurred).
- b) Phase 1B incur USD \$225.000 by December 31, 2020 (incurred).
- c) Phase 2 incur USD \$300,000 by December 31, 2022.
- d) Phase 3 incur USD \$400,000 by December 31, 2022.
- e) Phase 4 incur USD \$500,000 within 1 year of the Phase 4 Commencement Date.
- f) Phase 5 incur USD \$500,000 within 1 year of the Phase 5 Commencement Date.
- g) Phase 6 incur USD \$750,000 within 1 year of the Phase 6 Commencement Date.

In addition, the property owner will retain a 2.5% NSR. The Company has the option to purchase back 1.5% of the NSR for USD \$3,000,000 on a portion of the mineral claims (126/149) and USD \$1,000,000 on a portion of the mineral claims (23/149). The royalty to the project vendors is in addition to a further 0.5% royalty over a portion of the mineral claims (23/149).

The Company entered into a property option and joint venture agreement (the "Agreement") dated September 24, 2020 with Reyna Silver Corp. ("Reyna Silver").

Under the terms of the Agreement, Reyna Silver can earn a 75% interest in the Medicine Springs property by assuming and satisfying certain of the Company's commitments in the underlying option agreement dated August 20, 2017. Specifically, by paying USD \$875,000 and incurring exploration expenditures of approximately USD \$2,450,000 by December 31, 2023. Reyna Silver can earn an additional 5% by making a cash payment of USD \$1,000,000 to the Company by no later than December 31, 2023.

Upon completion, the Company and Reyna Silver will jointly own 100% of the Medicine Springs and will establish a joint venture.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in Canadian Dollars)

(Unaudited – Prepared by Management)

FOR THE SIX MONTHS ENDED OCTOBER 31, 2022

3. **EXPLORATION AND EVALUATION ASSETS** (cont'd...)

Secret Pass Gold Project

During the year ended April 30, 2020, the Company entered into an option agreement, subsequently amended, to acquire a 100% interest in the Secret Pass Gold Project located in northwestern Arizona.

Pursuant to the option agreement, the Company made the following consideration payments and therefore, acquired 100% interest in the Secret Pass Gold Project.

- a) within 5 working days following the exercise of the option, the Company will pay cash consideration of USD \$75,000 (paid);
- b) within 30 days following the exercise of the option, the Company will issue 200,000 common shares (issued and valued at \$80,000); and
- c) under the terms of the agreement, the Company will make the following additional payments:
 - USD \$175,000 on or before September 20, 2019 (paid); and
 - ii) USD \$125,000 on or before November 8, 2019 (paid).

There are no third-party royalties payable on future production from the project.

4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

	October 31, 20	22	April 30, 2022
Trade payables Accrued liabilities	\$ 298,6 70,9		178,392 84,900
	\$ 369,5	15 \$	263,292

5. CONVERTIBLE SECURITIES

On June 4, 2021, the Company issued unsecured zero-coupon non-redeemable convertible securities in the principal amount of \$1,075,476 (USD \$890,000) for a purchase price of \$966,089 (USD \$800,000). The securities are zero coupon or interest and mature two years from the date of issuance. The holder can convert, at any point in time, the securities into common shares at a price of \$0.06 per share ("Conversion Price").

In the event that the prevailing share price, at the time of a conversion is greater than the Conversion Price, the Company may elect to reduce the number of common shares issuable in that conversion by utilizing the prevailing share price as the conversion price instead of the Conversion Price. The "prevailing share price" will be determined by the investor as 85% of the average of five daily volume-weighted average prices of the common shares on the Canadian Stock Exchange ("CSE") during 20 consecutive trading days immediately prior to the date of the notice of conversion, rounded down to one tenth of a cent if the prevailing share price is less than \$0.20, or half a cent if the prevailing share price is greater than \$0.20.

Alternatively, in the event that the prevailing share price is less than the Conversion Price, the conversion will occur at the Conversion Price, and the Company will pay the investor an amount equal to the value of shares foregone as a result of the conversion price being the Conversion Price rather than the prevailing share price. The Company may elect to make this payment in common shares in lieu of cash, in its sole discretion.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in Canadian Dollars)

(Unaudited – Prepared by Management)

FOR THE SIX MONTHS ENDED OCTOBER 31, 2022

5. CONVERTIBLE SECURITIES (Cont'd...)

The Company will have a cash repayment right in relation to any conversion so that, instead of issuing conversion shares, the Company may, at its option, make a payment to the holder equal to the number of common shares that would have otherwise been issued in the conversion multiplied by the greater of the Conversion Price, the prevailing Share price, and the market value of the shares at that time.

The settlement of the convertible securities requires the issuance of shares that will equal USD \$890,000 of the principal amount of the debt. As a result, the settlement will result in a variable number of shares and the instrument is a financial liability even though it will be settled by the delivery of common shares and there is no contractual obligation to repay the securities in cash. In addition, the convertible securities are denominated in a currency (USD) that is different from the Company's functional currency (CAD) and therefore the instrument has an embedded derivative. Accordingly, the Company has elected to measure the entire instrument at FVTPL and has calculated an initial fair value of \$1,075,476 (USD \$890,000).

In connection with the convertible securities, the Company incurred transaction costs of \$446,152, recorded as expenses in profit or loss, and inclusive of the following:

- \$109,387 (USD \$90,000) discount on issuance;
- Issuance of 312,274 common shares (fair valued at \$187,365); and
- Issuance of 280,000 broker's warrants (fair valued at \$149,400).

Inputs used to calculate the fair value of the 280,000 broker's warrants were a share price of \$0.06, expected life of 4 years, volatility of 221% and a discount rate of 0.75%. Each broker's warrant entitles the holder to purchase one common share exercisable at the price of \$0.68509 until June 4, 2025.

In accordance with the agreement, on June 4, 2021, the Company issued to the holder 180,000 common shares with a fair value of \$108,000. These common shares will be counted towards any future conversions.

During the year ended April 30, 2022, the Company received notice to settle \$317,725 (USD \$250,000) of the principal through conversion exercise and issued 1,806,289 common shares.

During the period ended October 31, 2022, the Company received notice to settle \$308,528 (USD \$235,000) of the principal through conversion exercise and issued 10,552,992 common shares.

As at October 31, 2022, the fair value of the convertible securities was \$548,291, which resulted in a change in fair value of \$68,731 that was recognized in profit or loss.

	Total
Balance April 30, 2021	\$ _
Issuance of convertible securities	1,075,476
Adjustment for 180,000 common shares issued in advance of conversion	(108,000)
Conversion of 1,806,289 common shares	(317,725)
Change in fair value of convertible securities	 138,337
Balance April 30, 2022	788,088
Conversion of 10,552,992 common shares	(308,528)
Change in fair value of convertible securities	68,731
Balance October 31, 2022	\$ 548,291

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in Canadian Dollars)

(Unaudited – Prepared by Management)

FOR THE SIX MONTHS ENDED OCTOBER 31, 2022

6. SHARE CAPITAL

Authorized: Unlimited common shares, without par value

During the period ended October 31, 2022, the Company:

- i) issued 10,552,992 common shares fair valued at \$308,528 pursuant to the convertible securities (Note 5).
- ii) closed a private placement of 4,550,000 common shares and 3,150,000 warrants for gross proceeds of \$227,500. Each warrant is exercisable into one common share at a price of \$0.10 per share until July 27, 2024.

During the year ended April 30, 2022, the Company:

- i) issued 312,274 common shares fair valued at \$187,365 as transaction costs for the convertible securities.
- ii) issued 1,986,289 common shares fair valued at \$425,725 pursuant to the convertible securities (Note 5).
- iii) issued 187,348 common shares fair valued at \$46,837 pursuant to the option payment of the Medicine Spring Project (Note 3).

Stock options

The Company has a stock option plan in place under which it is authorized to grant options to executive officers and directors, employees and consultants enabling them to acquire up to 10% of the then issued and outstanding common stock of the Company. Under the plan, the exercise price of each option will not be less than the market price of the Company's stock as calculated on the date of grant. The options can be granted for a maximum term of 10 years.

A summary of changes in stock options is as follows:

	Number of Options	Weighted Average Exercise Price
Outstanding as at April 30, 2021	895,407	\$ 0.70
Outstanding as at April 30, 2022 and October 31, 2022	895,407	\$ 0.70

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in Canadian Dollars)

(Unaudited – Prepared by Management)

FOR THE SIX MONTHS ENDED OCTOBER 31, 2022

6. SHARE CAPITAL (cont'd...)

Stock options (Cont'd...)

As at October 31, 2022, the following options were outstanding and exercisable:

Number of Options	Exer	cise Price	Expiry Date	Exercisable
255,000	\$	1.00	November 7, 2023	255,000
390,407	\$	0.50	July 23, 2025	390,407
200,000	\$	0.70	December 10, 2025	200,000
50,000	\$	0.70	January 13, 2026	50,000
895,407				895,407

Stock options issued are included in the share-based payment reserve.

Warrants

A summary of changes in warrants is as follows:

	Number of Warrants	Weighted Average Exercise Price
Outstanding as at April 30, 2021	6,192,178	\$ 0.80
Granted	280,000	0.69
Outstanding as at April 30, 2022	6,472,178	0.75
Granted	3,150,000	0.10
Outstanding as at October 31, 2022	9,622,178	\$ 0.54

Warrants issued and classified as equity are included in the Share-based payment reserve. As at October 31, 2022, the following warrants were outstanding and exercisable:

Number of Warrants	Exer	cise Price	Expiry Date
			1 0
342,000	\$	0.75	July 4, 2024
3,150,000	\$	0.10	July 27, 2024
1,262,777	\$	0.75	January 22, 2025
280,000	\$	0.685	June 4, 2025
4,373,001	\$	0.75	August 19, 2025
214,400	\$	0.75	August 19, 2025
9,622,178			-

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in Canadian Dollars)

(Unaudited – Prepared by Management)

FOR THE SIX MONTHS ENDED OCTOBER 31, 2022

7. TRANSACTIONS WITH RELATED PARTIES

The Company defines key management personnel as officers and directors. During the period ended October 31, 2022, the Company:

- i) paid or accrued management fees of \$45,000 (2021 \$45,000) to a director of the Company.
- ii) paid or accrued management fees of \$45,000 (2021 \$45,000) to the Chief Executive Officer ("CEO") of the Company.
- iii) paid or accrued professional fees of \$6,000 (2021 \$6,000) to the Chief Financial Officer ("CFO") of the Company.
- iv) recorded share-based compensation of \$Nil (2021 \$3,558) related to options granted to officers and directors of the Company.

Included in accounts payable and accrued liabilities as at October 31, 2022 is \$97,637 (April 30, 2022 - \$43,243) owed to officers of the Company.

Included in prepaid expenses as at October 31, 2022 is \$Nil (April 30, 2022 - \$11,320) advanced to an officer and a director of the Company.

8. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

The Company has applied a three-level hierarchy to reflect the significance of the inputs used in making fair value measurements. The three levels of fair value hierarchy are:

- Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities;
- Level 2 Inputs other than quoted prices that are observable for assets or liabilities, either directly or indirectly; and
- Level 3 Inputs for assets or liabilities that are not based on observable market data.

The Company's financial instruments consist of cash, accounts payable and accrued liabilities, and convertible securities. The fair value of these financial instruments, other than cash, and convertible securities approximates their carrying values due to the short-term nature of these instruments. Cash is measured at fair value using level 1 inputs. Convertible securities are measured using level 2 inputs as it uses observable inputs other than quoted prices included within level 1.

The Company is exposed to a variety of financial risks by virtue of its activities including currency, credit, interest rate, liquidity and other price risk.

a) Currency risk

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. A portion of the Company's expenses are denominated in US dollars. As the Company's functional and presentation currency is the Canadian dollar, the Company is exposed to risk from changes in the US dollar exchange rate.

At October 31, 2022, the Company had Canadian dollar equivalent cash of \$7,505 (April 30, 2022 - \$24,412), accounts payable and accrued liabilities of \$369,515 (April 30, 2022 - \$263,292), and convertible securities of \$548,291 (April 30, 2022 - \$788, 088) which were denominated in US dollars.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in Canadian Dollars)

(Unaudited – Prepared by Management)

FOR THE SIX MONTHS ENDED OCTOBER 31, 2022

8. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Cont'd...)

a) Currency risk (cont'd...)

Sensitivity Analysis

Management has completed a sensitivity analysis to estimate the impact on profit or loss for the period which a change in foreign exchange rates during the period ended October 31, 2022 and 2021 would have had. At October 31, 2022, the Company is exposed to nominal foreign currency risk.

b) Credit risk

Credit risk is the risk of financial loss associated with the counterparty's inability to fulfill its payment obligations. Financial instruments that potentially subject the Company to concentrations of credit risks consist principally of cash. To minimize the credit risk the Company places these instruments with a high-quality financial institution.

c) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk on the variable rate of interest earned on bank deposits. The fair value interest rate risk on bank deposits is insignificant as the deposits are short term.

The Company has not entered into any derivative instruments to manage interest rate fluctuations.

d) Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity risk is to ensure it has a planning and budgeting process in place to determine the funds required to support its ongoing operations and capital expenditures. The Company ensures that sufficient funds are raised from private placements, option exercises and warrant exercises to meet its working capital requirements, after taking into account existing cash and expected exercise of share purchase warrants and options. Management believes that it will be successful in raising the necessary funds however, given the current market conditions, management believes that the raising of the required funds will take longer than is normal and will be at prices that may be less than desirable. There are no assurances that additional funds will be available on terms acceptable to the Company or at all. The Company does not have significant liquidity risk as all of its financial liabilities are current in nature.

e) Other price risk

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices, whether those changes are caused by factors specific to the individual financial instrument or its issuer or by factors affecting all similar financial instruments traded in the market. The Company is not exposed to material price risk at October 31, 2022.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in Canadian Dollars)

(Unaudited – Prepared by Management)

FOR THE SIX MONTHS ENDED OCTOBER 31, 2022

9. CAPITAL MANAGEMENT

The Company defines capital that it manages as its shareholders' equity, which totaled \$1,894,324 as at October 31, 2022 (April 30, 2022 - \$1,678,572). When managing capital, the Company's objective is to ensure the entity continues as a going concern as well as to maintain optimal returns to shareholders and benefits for other stakeholders. The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company, in order to support the acquisition and exploration of exploration and evaluation assets. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business.

The properties in which the Company currently has an interest are in the exploration stage; as such the Company has historically relied on the equity markets to fund its activities. The Company will continue to assess new properties and seek to acquire an interest in additional properties if it feels there is sufficient geologic or economic potential and if it has adequate financial resources to do so.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. The Company did not change its approach to capital management during the period ended October 31, 2022.

10. SEGMENTED INFORMATION

The Company's primary business activity is the acquisition and exploration of exploration and evaluation assets. Geographic information is as follows:

	October 31, 2022	April 30, 2022
Exploration and evaluation assets United States	\$ 2,680,014 \$	2,676,090

11. SUBSEQUENT EVENTS

Subsequent to October 31, 2022, the Company:

- i) issued 5,760,250 common shares pursuant to the conversion of the convertible securities.
- ii) entered into an agreement to its 25% interest in the Medicine Springs to Reyna Silver.

Upon completion of the transaction, Reyna Silver will have the option to acquire the remaining 75% interest by satisfying the property option and joint venture agreement dated September 24, 2020 detailed in Note 5.

In consideration of the 25% interest in Medicine Spring, Reyna Silver will make these considerations as follows:

- a) cash payment of US\$100,000.
- b) 6,000,000 common shares of Reyna Silver, which will be subjected to contractual resale restriction over a twenty-four month period.
- c) 1% NSR royalty over Medicine Springs Project licenses. The royalty to the Company will not become effective until Reyna Silver has completed all the obligations in the Medicine Springs underlying option agreement, and owns 100% interest of the project. Reyna Silver retains the right to purchase 0.5% NSR Royalty for a cash consideration of US2,500,000 at any time in the future.

The Company has agreed to pay a finders' fee to an arms-length party of \$40,000 in common shares.